The Indiana University School of Medicine has forged a $5 million agreement with Indianapolis-based Eli Lilly and Co. (NYSE: LLY) to collaborate on research of a variety of diseases, including inflammatory bowel disease and psoriasis.
The five-year agreement aims to gain an understanding of molecular and cellular changes occurring in patients who use some of Lilly’s current medications to treat autoimmune diseases.
IU says Lilly will provide de-identified patient sample data from autoimmune clinical studies.
The school will analyze the samples, utilizing its informatics, statistics, and clinical pharmacology capabilities.
The partners will also utilize the Indiana Clinical and Translational Sciences Institute, which provides research support and infrastructure to researchers across the state.
“It makes sense for us to collaborate with IU School of Medicine and the Indiana Clinical and Translational Sciences Institute, located in our own backyard,” said Patrik Jonsson, senior vice president and president of Lilly Bio-Medicines. “IU has a positive reputation for analytics and informatics that we hope will benefit our autoimmune pipeline for the patients it serves.”
A joint steering committee will review and approve projects on a case by case basis, with the first to begin this month.